{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:49:22Z","timestamp":1761518962996},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s12094-010-0533-5","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T12:00:12Z","timestamp":1276603212000},"page":"450-452","source":"Crossref","is-referenced-by-count":2,"title":["Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine"],"prefix":"10.1007","volume":"12","author":[{"given":"Silvia","family":"Antol\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Dopico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Quind\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Reboredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Carral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"533_CR1","unstructured":"Eli Lilly and Company (1998) GEMZARp (gemcitabine HCI) for injection (prescribing information). Eli Lilly and Company, Indianapolis. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/onctools\/labels.cfm?GN=gemcitabine Accessed 15 Dec 2008"},{"key":"533_CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00001813-199803000-00001","volume":"9","author":"M.S. Aapro","year":"1998","unstructured":"Aapro MS, Martin C, Hatty S (1998) Gemcitabine \u2014 a safety review. Anticancer Drugs 9:191\u2013201","journal-title":"Anticancer Drugs"},{"key":"533_CR3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.0767-3981.2003.00206.x","volume":"18","author":"F. Barlesi","year":"2004","unstructured":"Barlesi F, Villani P, Doddoli C et al (2004) Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 18:85\u201391","journal-title":"Fundam Clin Pharmacol"},{"key":"533_CR4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q","volume":"80","author":"N. Pavlakis","year":"1997","unstructured":"Pavlakis N, Bell DR, Millward MJ, Levi JA (1997) Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80:286\u2013291","journal-title":"Cancer"},{"key":"533_CR5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1378\/chest.114.6.1779","volume":"114","author":"N.J. Els Vander","year":"1998","unstructured":"Vander Els NJ, Miller V (1998) Succesful treatment with gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 114:1779\u20131781","journal-title":"Chest"},{"key":"533_CR6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.2169\/internalmedicine.42.1022","volume":"42","author":"K. Maniwa","year":"2003","unstructured":"Maniwa K, Tanaka E, Inove T et al (2003) An autopsy case of acute pulmonary toxicity associated with gemcitabine. Intern Med 42:1022\u20131025","journal-title":"Intern Med"},{"key":"533_CR7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1016214032272","volume":"20","author":"D.F. Roychowdhury","year":"2002","unstructured":"Roychowdhury DF, Cassidy CA, Peterson P, Arning M (2002) A report of serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 20:311\u2013315","journal-title":"Invest New Drugs"},{"key":"533_CR8","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1378\/chest.06-1464","volume":"131","author":"S. Hariharan","year":"2007","unstructured":"Hariharan S, Welsh C (2007) Shortness of breath and hypoxemia after chemotherapy with carboplatin and gemcitabine. Chest 131:1978\u20131981","journal-title":"Chest"},{"key":"533_CR9","first-page":"2051","volume":"106","author":"Belknap","year":"2006","unstructured":"Belknap, Steven M, Kuzwel, Timothy M, Yarnold Paul R et al (2006) Clinical features and correlates of gemcitabine associated lung injury. Findings from the radar project. Cancer 106:2051\u20132057","journal-title":"Findings from the radar project. Cancer"},{"key":"533_CR10","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/sj.bjc.6603161","volume":"94","author":"A. Czarnecki","year":"2006","unstructured":"Czarnecki A (2006) Pulmonary toxicity in patients treated with gemcitabine and a combination of gemcitabine and a taxane: investigation of a signal using postmarketing data. Br J Cancer 94: 1759\u20131760","journal-title":"Br J Cancer"},{"key":"533_CR11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0761-8417(07)78425-0","volume":"63","author":"A. Bonnichon","year":"2007","unstructured":"Bonnichon A, Vedrine L, Aletti M et al (2007) Favorable outcome of gemcitabine-induced acute respiratory distress syndrome [in French] Rev Pneumol Clin 63:379\u2013383","journal-title":"Rev Pneumol Clin"},{"key":"533_CR12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/CAD.0b013e3281ceabec","volume":"18","author":"S. Boeck","year":"2007","unstructured":"Boeck S, Hausmann A, Reibke R et al (2007) Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 18:1109\u20131111","journal-title":"Anticancer Drugs"},{"key":"533_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10637-006-9030-7","volume":"25","author":"S.A. Veltkamp","year":"2007","unstructured":"Veltkamp SA, Terwogt JMM et al (2007) Severe pulmonary toxicity in patients with leio myosarcoma after treatment with gemcitabine and docetaxel. Investigational New Drugs 25:279\u2013281","journal-title":"Investigational New Drugs"},{"key":"533_CR14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.rmed.2005.08.002","volume":"100","author":"S. Davidoff","year":"2006","unstructured":"Davidoff S, Shah RD, Arunabh T (2006) Gemcitabine-induced respiratory failure associated with elevated erythrocyte sedimentation rate (ESR). Respir Med 100:760\u2013763","journal-title":"Respir Med"},{"key":"533_CR15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.lungcan.2003.12.004","volume":"44","author":"C. Kouroussis","year":"2004","unstructured":"Kouroussis C, Mavroudis D, Kakolyris S et al (2004) High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dosefinding study. Lung cancer 44:363\u2013368","journal-title":"Lung cancer"},{"key":"533_CR16","first-page":"123","volume":"58","author":"V. Mommens","year":"2003","unstructured":"Mommens V, Bosquee L, D\u2019Orio V (2003) Clinical case of the month. Pulmonary toxicity due to gemcitabine for NSCLC with brain metastasis. Rev Med Liege 58:123\u2013126","journal-title":"Rev Med Liege"},{"key":"533_CR17","first-page":"645","volume":"19","author":"J. Sabria-Trias","year":"2002","unstructured":"Sabria-Trias J, Bonnaud F, Sioniac M (2002) Severe intersticial pneumonitis related to gemcitabine. Rev Mal Respir 19:645\u2013647","journal-title":"Rev Mal Respir"},{"key":"533_CR18","first-page":"17","volume":"132","author":"M. Foerger","year":"2002","unstructured":"Foerger M, Gunz A, Speich R, Pestalozzi BC (2002) Gemcitabine-related pulmonary toxicity. Swiss Med Wkly 132:17\u201320","journal-title":"Swiss Med Wkly"},{"key":"533_CR19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00000421-200202000-00005","volume":"25","author":"M.F. Rosado","year":"2002","unstructured":"Rosado MF, Kett DH, Schein RM et al (2002) Severe pulmonary toxicity in a patient treated with gemcitabine. Am J Clin Oncol 25:31\u201333","journal-title":"Am J Clin Oncol"},{"key":"533_CR20","first-page":"851","volume":"30","author":"B. Lavigerie de","year":"2001","unstructured":"de Lavigerie B, Joasson JM (2001) Acute respiratory distress syndrome after antineoplastic chemotherapy. Probable role of gemcitabine. Presse Med 30:851\u2013854","journal-title":"Presse Med"},{"key":"533_CR21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0300-2977(00)00029-2","volume":"56","author":"R.K. Linskens","year":"2000","unstructured":"Linskens RK, Golding RP, Van Groeningen CJ, Giaccone G (2000) Severe acute lung injury induced by gemcitabine. Neth J Med 56:232\u2013235","journal-title":"Neth J Med"},{"key":"533_CR22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1183\/09031936.98.11020504","volume":"11","author":"A. Marruchella","year":"1998","unstructured":"Marruchella A, Fiorenzano G, Merizzi A et al (1998) Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 11:504\u2013506","journal-title":"Eur Respir J"},{"key":"533_CR23","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.1995.13.11.2731","volume":"13","author":"J. Carmichael","year":"1995","unstructured":"Carmichael J, Possinger K, Philip P et al (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13:2731\u20132736","journal-title":"J Clin Oncol"},{"key":"533_CR24","unstructured":"ClinicalTrials.gov (2008). Available at http:\/\/www.clinicaltrials.gov Accessed 15 Dec 2008"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0533-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-010-0533-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0533-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:50:49Z","timestamp":1559433049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-010-0533-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1007\/s12094-010-0533-5","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}